About Us

About Us

We are a team of architects, engineers, scientists
We believe in science and in service to the others. we value science through our engagement on creating lab workplace solution and funding support, so that life science companies can focus their time, investment and energy on science.
We are enthusiastic to innovative our work as much as scientists to their discovery.

Zhang XI

Chairman | CEO
Zhang Xi graduated with a Masters degree from ETH University, Zürich in 2006, and founded EXH Design Shanghai the same year. In 2016 she cofounded EXH design Zurich. After completed various large scale laboratories projects for pharma companies in Europe and China, she founded Superlab Suisse in 2019 in Zurich, Switzerland. 

Dr. Konstantinos Efthymiopoulo

Board Member | Business Development
Dr. Efthymiopoulos is currently the Managing Director of PLUS Life Sciences Consulting and a Board Director of Metis Precision Medicine. He has more than 30 years international experience that covers the entire range of activities spanning research through to clinical development, manufacturing, registration and product launch, applied in most major therapeutic areas as well as in drug delivery, therapeutic vaccines, diagnostics and medical devices. He has worked in large pharmaceutical, biotech and VC-backed companies at increasingly senior levels. These have culminated in C-suite and Board positions such as the Chairman of the Board of Biopôle and Eporgen Life Sciences, the CEO and Board Director of Funxional Therapeutics as well as the CSO and Head of R&D of Eurand. He graduated in Pharmacy from the University of Athens, holds a Ph.D. in Pharmacokinetics, M.Sc. degrees in Pharmacology and Industrial Pharmacy from the University of Strasbourg as well as an MBA from London Business School.

Dr. Thilo Schröder

Board Member
Thilo Schroeder, Ph.D. has a passion for precision medicines in cancer with a focus on identifying first and best-in-class targeted therapies regardless of drug modality. Since 2012, Thilo has helped grow and shape Nextech as a leading oncology focused venture firm.
Thilo is a board member of Revolution Medicines (NASDAQ: RVMD), PMV Pharma (NASDAQ: PVMP), Circle Pharma, Silverback Therapeutics (NASDAQ: SBTX), MOMA Therapeutics. Past board seats include Blueprint Medicines (NASDAQ: BPMC), Peloton Therapeutics (acquired by Merck) and IDEAYA Biosciences (NASDAQ: IDYA). Thilo is a past board observer of BlackDiamond Therapeutics (NASDAQ: BDTX).
Thilo began his biotech career at the pioneering cancer immunology company Micromet (acquired by Amgen) while studying at Ecole Supérieure de Biotechnologie de Strasbourg, conducted research at the University of Sydney and obtained his Ph.D. from the University of Zurich, focused on protein engineering in the development of Designed Ankyrin Repeat Proteins (DARPins), a technology developed by Molecular Partners (SWX:MOLN).

Our Partners